enGene Therapeutics Inc.

ENGN Nasdaq CIK: 0001980845

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation Canada (Federal Level)
Country Quebec, Canada
Business Address 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, ,
Mailing Address 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, ,
Phone (514) 332-4888
Fiscal Year End 1031
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 9, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
10-Q Quarterly financial report March 9, 2026 View on SEC
424B5 Prospectus supplement March 9, 2026 View on SEC
S-3 Shelf registration for future offerings February 19, 2026 View on SEC
10-K/A Annual report amendment February 19, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC

Annual Reports

10-K December 22, 2025
  • The company transitioned its CEO in February 2024, signaling potential new strategic directions.
  • enGene completed private placements in February and October 2024 and announced a public offering for November 2025.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.